Patents Represented by Attorney Albert P. Pennie & Edmonds Halluin
-
Patent number: 6100054Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.Type: GrantFiled: May 30, 1995Date of Patent: August 8, 2000Assignee: Baylor College of MedicineInventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
-
Patent number: 5766939Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.Type: GrantFiled: May 30, 1995Date of Patent: June 16, 1998Assignee: Baylor College of MedicineInventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
-
Patent number: 5759828Abstract: The present invention provides the nucleotide sequences of Acetobacter operons, cdg operons encoding genes for the biosynthesis and degradation of cyclic diguanosine monophosphate (c-di-GMP). Specifically, the nucleotide sequences and deduced amino acid sequences of 3 phosphodiesterases isozymes, 3 diguanylate cyclase isozymes, and 2 polypeptides of unidentified function are provided. Also provided for are various strains of microorganisms, including Acetobacter cells genetically manipulated so as to produce elevated and/or reduced levels of one or more cdg operon encoded proteins.Type: GrantFiled: September 20, 1994Date of Patent: June 2, 1998Assignee: WeyerhaeuserInventors: Rony Tal, David H. Gelfand, Roger D. Calhoon, Arie Ben-Bassat, Moshe Benziman, Hing Cheung Wong
-
Patent number: 5716508Abstract: The present invention relates to an electrophoresis media comprising a gel and a compound capable of restricting the diffusion of water within the gel. Diffusion restricting compounds useful in the present invention include but are not limited to polyols, polymeric alcohols, polysaccharides, polyoxyethylene ethers, polyamines, polypeptides, gums, zwiterionic detergents and mixtures thereof. The present method relates to any electrophoresis media and includes but is not limited to polyacrylamide, agarose, starch, cellulose acetate and sepharose. A further embodiment of the present invention relates to a stacking gel wherein a diffusion restricting compound is used to prevent diffusion of water between the stack gel and resolving gel. The addition of a diffusion restricting compound to the stacking gel has the particular advantage of causing the stacking gel to become opaque, thereby facilitating the addition of samples to the gel.Type: GrantFiled: September 9, 1993Date of Patent: February 10, 1998Assignee: Glyko IncorporatedInventor: Christopher M. Starr
-
Patent number: 5646019Abstract: The present invention relates to an improved method for producing primed nucleic acid templates. Specifically, it relates to a method, compositions and kits therefor, of increasing the specificity of primer extension reactions by hybridizing primer to template in the presence of single-stranded nucleic acid binding protein.Type: GrantFiled: April 7, 1994Date of Patent: July 8, 1997Assignee: StratageneInventors: Kirk B. Nielson, Eric J. Mathur
-
Patent number: 5637483Abstract: A method of altering the specific, systemic immune response of an individual to a target antigen by the co-administration of a cytokine an adhesion or accessory molecule and the target antigen. The target antigen may be a tumor cell, a tumor cell antigen, an infectious agent or other foreign antigen, or other antigens to which an enhanced systemic immune response is desirable. Alternatively, the antigen may be a non-foreign antigen when a suppression of a systemic immune response is desired. The resulting systemic immune response is specific for the target antigen.Type: GrantFiled: June 23, 1994Date of Patent: June 10, 1997Assignees: Whitehead Institute for Biomedical Research, Johns Hopkins University School of MedicineInventors: Glenn Dranoff, Richard C. Mulligan, Drew Pardoll
-
Patent number: 5637621Abstract: The invention provides fungicidal compounds having the general formula:X.sub.1 -A.sub.1 -B.sub.1 -C-B.sub.2 -A.sub.2 -X.sub.2 (I)wherein X.sub.1 is an amidine, a guanidine, or an imidazole group.A.sub.1 is either a five-membered aromatic ring, a six-membered aromatic ring, a fusion of two five-membered aromatic rings, a fusion of 2 six-membered aromatic rings, or a fusion of a six-membered aromatic ring and a five-membered aromatic ring;B.sub.1 is either O (oxygen) or absent; C is a straight chain alkyl comprising 1-8 carbons; B.sub.2 is either O (oxygen) or absent; A.sub.2 is either a five-membered aromatic ring, a six-membered aromatic ring, a fusion of two five-membered aromatic rings, a fusion of 2 six-membered aromatic rings, or a fusion of a six-membered aromatic ring and a five-membered aromatic ring; and X.sub.2 is an amidine, a guanidine, or an imidazole.Type: GrantFiled: November 14, 1994Date of Patent: June 10, 1997Assignee: NZYM, Inc.Inventors: Joel Bolonick, Terrance J. Leighton, Ida K. Yu
-
Patent number: 5631151Abstract: The present invention is directed to a process for producing melanins, their precursors and their analogues, hereinafter referred to generically as melanins. According to the invention, melanins are produced in amounts greater than about 3.3 grams wet weight per liter of growth medium. The enhanced production of melanin can be achieved by manipulating the constituents of the growth medium, and/or attenuating fermentations conditions, and/or by genetically engineering microorganisms to produce melanins, and/or mutating the microorganisms.Type: GrantFiled: March 20, 1992Date of Patent: May 20, 1997Assignee: Biosource Technologies, Inc.Inventors: Guy della-Cioppa, Stephen J. Garger, Jr., Genadie G. Sverlow, Thomas H. Turpen, Laurence K. Grill, Miles R. Chedekel, Monto H. Kumagai
-
Patent number: 5629348Abstract: The invention provides fungicidal compounds having the general formula:X.sub.1 -A.sub.1 -B.sub.1 -C-B.sub.2 -A.sub.2 -X.sub.2 (I)wherein X.sub.1 is an amidine, a guanidine, or an imidazole group.A.sub.1 is either a five-membered aromatic ring, a six-membered aromatic ring, a fusion of two five-membered aromatic rings, a fusion of 2 six-membered aromatic rings, or a fusion of a six-membered aromatic ring and a five-membered aromatic ring;B.sub.1 is either O (oxygen) or absent; C is a straight chain alkyl comprising 1-8 carbons; B.sub.2 is either O (oxygen) or absent; A.sub.2 is either a five-membered aromatic ring, a six-membered aromatic ring, a fusion of two five-membered aromatic rings, a fusion of 2 six-membered aromatic rings, or a fusion of a six-membered aromatic ring and a five-membered aromatic ring; and X.sub.2 is an amidine, a guanidine, or an imidazole.Type: GrantFiled: November 14, 1994Date of Patent: May 13, 1997Assignee: NZYM, Inc.Inventors: Joel Bolonick, Terrance J. Leighton, Ida K. Yu
-
Patent number: 5605824Abstract: The present invention relates to an improved composition for hybridizing polynucleotides with complementary nucleic acid sequences. Specifically, it relates to a composition for of increasing the specificity of a polynucleotide hybridization reaction in the presence of single-stranded nucleic acid binding protein.Type: GrantFiled: June 16, 1993Date of Patent: February 25, 1997Assignee: StratageneInventors: Kirk B. Nielson, Eric J. Mathur
-
Patent number: 5593859Abstract: The invention is transfected cells, substantially all of which contain at least one human collagen gene and express fibrillar collagen molecules derived using methods for synthesizing collagen and collagen fibrils in said cell lines, and methods for treatment of disorders in humans using said collagen derived from said stable cell lines.Type: GrantFiled: August 11, 1994Date of Patent: January 14, 1997Assignee: Thomas Jefferson UniversityInventors: Darwin J. Prockop, Leena Ala-Kokko, Andrzej Fertala, Aleksander Sieron, Kari I. Kivirikko, Amy Geddis, Taina Pihlajaniemi
-
Patent number: 5591839Abstract: Polynucleotide sequences encoding enzymes that possess .alpha.2-3 neuraminidase activity are provided. Of particular interest are polynucleotide sequences encoding an enzyme having .alpha.2-3 neuraminidase activity and naturally produced by the bacteria Streptococcus pneumoniae. Recombinant DNA expression of enzymes possessing .alpha.2-3 specific neuraminidase activity is also described, including methods, recombinant host cells and a genetic construction. The invention also provides a purified enzyme having .alpha.2-3 neuraminidase activity from Streptococcus pneumoniae, wherein the enzyme is isolated from S. pneumoniea cultures. Another aspect of this invention is to provide methods of isolating genes encoding enzymes having neuraminidase activity, particularly .alpha.2-3 neuraminidase activity. The gene isolation methods of the invention comprise the step of labeling a hybridization probe derived from the neuraminidase coding portion of plasmid pND-1.Type: GrantFiled: August 18, 1994Date of Patent: January 7, 1997Assignee: Glyko, Inc.Inventors: Harvey I. Miller, John C. Klock, Christopher M. Starr
-
Patent number: 5589392Abstract: A system for regulating expression of eukaryotic genes in cells is described. The system contains two recombinant DNA molecules, a first molecule that encodes a nucleus-targeted inducible repressor polypeptide, and a second molecule that encodes an operator-regulated reporter polypeptide. Transgenic animals containing the system, and methods for using the system are also described.Type: GrantFiled: November 29, 1993Date of Patent: December 31, 1996Assignee: StratageneInventor: Jay M. Short
-
Patent number: 5589367Abstract: The present invention is directed to recombinant plant viral nucleic acids and to hosts infected thereby. The recombinant plant viral nucleic acids comprise a native plant viral subgenomic promoter, at least one non-native plant viral subgenomic promoter, a plant viral coat protein coding sequence, and optionally, at least one non-native nucleic acid sequence to be transcribed or expressed in the infected host plant. The recombinant plant viral nucleic acids are stable, capable of systemic infection and capable of stable transcription or expression in the plant host of the non-native nucleic acid sequences.Type: GrantFiled: January 19, 1994Date of Patent: December 31, 1996Assignee: Biosource Technologies, Inc.Inventors: Jon Donson, William O. Dawson, George L. Granthan, Thomas H. Turpen, Ann M. Turpen, Stephen J. Garger, Laurence K. Grill
-
Patent number: 5580776Abstract: Genetically engineered or transduced hepatocytes which express genetic material of interest introduced or incorporated into them, as well as methods of producing, transplanting and using the genetically engineered hepatocytes. The genetic material of interest can be incorporated through use of a vector, such as a recombinant retrovirus, which contains the genetic material of interest, or by other means.Type: GrantFiled: February 25, 1994Date of Patent: December 3, 1996Assignees: Howard Hughes Medical Institute, Whitehead Institute for Biomedical ResearchInventors: James M. Wilson, Richard C. Mulligan
-
Patent number: 5571697Abstract: The subject invention provides for the production of lactoferrins and lactoferrin polypeptide fragments using the host cells Aspergillus in combination with novel plasmid constructs. More specifically, the subject invention provides novel vector constructs capable of producing lactoferrins and lactoferrin polypeptide fragments in Aspergillus host cells. More particularly, the subject invention provides for novel plasmid constructs suitable for use with Aspergillus and especially Aspergillus awamori, niger and oryzae host cells, which enables them to produce large amounts of recombinant lactoferrins and lactoferrin polypeptide fragments.Type: GrantFiled: November 2, 1994Date of Patent: November 5, 1996Assignee: Baylor College of Medicine Texas Medical CenterInventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley
-
Patent number: 5571896Abstract: The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for human lactoferrin protein. Methods for the production of human lactoferrin protein in A. Oryzae are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant human lactoferrin protein.Type: GrantFiled: May 27, 1994Date of Patent: November 5, 1996Assignee: Baylor College of MedicineInventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
-
Patent number: 5571691Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.Type: GrantFiled: October 28, 1993Date of Patent: November 5, 1996Assignee: Baylor College of MedicineInventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
-
Patent number: 5545552Abstract: Purified thermostable Pyrococcus furiosus DNA polymerase that migrates on a non-denaturing polyacrylamide gel faster than phosphorylase B and Taq polymerase and more slowly than bovine serum albumin and has an estimated molecular weight of 90,000-93,000 daltons when compared with a Taq polymerase standard assigned a molecular weight of 94,000 daltons.Type: GrantFiled: April 19, 1995Date of Patent: August 13, 1996Assignee: StratageneInventor: Eric J. Mathur
-
Patent number: 5529909Abstract: The present invention relates to a nucleic acid sequence that encodes a fusion enzyme of tyrosinase and a tyrosinase activator protein. Further, the present invention also relates to the amino acid sequence which is encoded by the nucleic acid sequence of the fusion enzyme. The fusion enzyme may also include a linker positioned between the amino acid sequences of the tyrosinase and the tyrosinase activator protein. Still further, the present invention also relates to a vector useful for introducing the nucleic acid sequence encoding the fusion enzyme into an organism. Still further, the present invention relates to melanins made by the fusion enzyme and a method for making melanins using the fusion enzyme.Type: GrantFiled: November 12, 1993Date of Patent: June 25, 1996Assignee: Biosource Technologies, Inc.Inventors: Guy della-Cioppa, Monto Kumagai